JGC
KPTI icon

J. Goldman & Co’s Karyopharm Therapeutics KPTI Stock Holding History

J. Goldman & Co’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-3,747
Closed -$821K – 431
2020
Q3 		$821K Buy
+3,747
New +$917K 0.06% 225

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

J. Goldman & Co's KPTI Position: Q4 2023 in Review

J. Goldman & Co sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 8,000 shares — an estimated $161K sold.

J. Goldman & Co first reported a position in KPTI in Q3 2019 and held it in 12 quarters. The position peaked at $14M in Q1 2021. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • J. Goldman & Co reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • J. Goldman & Co sold 8,000 Karyopharm Therapeutics shares in Q4 2023, an estimated $161K.
  • J. Goldman & Co first reported a position in Karyopharm Therapeutics in Q3 2019 and held it in 12 quarters.
  • J. Goldman & Co's Karyopharm Therapeutics position peaked at $14M in Q1 2021.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on J. Goldman & Co's 13F filing for Q4 2023, filed 14 Feb 2024.